Postdoc Immunology: Senolytics for Fibrotic Lung

Eli Lilly and Company; San Francisco (CA); On-site; USD 58,000 - 123,000; Full time

Benefits offered by this job

401(k) plan

Pension

Vacation benefits

Medical benefits

Life insurance

Flexible benefits

Well-being benefits

Job summary

Eli Lilly and Company is seeking a postdoctoral scientist to advance precision therapies at the intersection of cellular senescence biology, fibrosis, and immune-based therapeutics. Your work will contribute to a high-visibility research program and open new therapeutic avenues in the senolytics space.

The role spans cellular models, in vivo fibrosis models, and human tissue, with opportunities to publish as first author and present at major conferences.

Qualifications

• PhD in Immunology, Cell Biology, Molecular Biology, Aging Biology, or closely related field.
• Experience with cellular senescence and fibrosis or related areas such as aging biology, immunology or analytical approaches.
• Strong publication record demonstrating scientific productivity and independence.
• Authorized to work in the United States on a full-time basis; Lilly will not sponsor visas.

Responsibilities

• Establish and characterize models of cellular senescence in fibrotic lung disease.
• Identify cell-surface markers distinguishing pathological senescent cells.
• Develop immune effector-based strategies to eliminate senescent cells.
• Evaluate senolytic efficacy in human tissue and in vivo models.
• Collaborate with cross-functional teams and external partners; present findings at conferences.

Skills

Immunology

Cell biology

Aging biology

Single-cell analysis

Proteomics

Education

PhD in Immunology / Cell Biology / Aging Biology

Tools

iPSC culture

In vivo fibrosis models

Flow cytometry

Job description

Eli Lilly and Company is seeking a postdoctoral scientist to advance precision therapies at the intersection of cellular senescence biology, fibrosis, and immune-based therapeutics. Your work will contribute to a high-visibility research program and open new therapeutic avenues in the senolytics space.

The role spans cellular models, in vivo fibrosis models, and human tissue, with opportunities to publish as first author and present at major conferences.